neratinib
Neratinib Shows Promise in Certain Metastatic Breast Cancer Cases
A combination of neratinib, fulvestrant and trastuzumab showed encouraging clinical activity in patients with ...
MARCH 9, 2022
Nerlynx Granted Expanded Indication for Advanced/Metastatic HER2+ Breast Cancer
The FDA approved neratinib (Nerlynx, Puma) in combination with capecitabine for adults with advanced or metastatic ...
FEBRUARY 27, 2020
Neratinib + Capecitabine Has Potential for HER2+ Breast Cancer Brain Mets
Neratinib plus capecitabine is an active combination for HER2-positive breast cancer metastatic to the CNS, ...
SEPTEMBER 27, 2017
HER2 Inhibitor Yields Variable ORR Across Ca Types
Washington—In a trial that treated a variety of advanced solid tumors with a targeted HER2 inhibitor, the ...
JULY 19, 2017
Nerlynx Approved for HER2+ Breast Cancer
The FDA has approved neratinib for extended adjuvant therapy in early-stage HER2-positive breast cancer.
JULY 17, 2017
How I Manage Adjuvant Therapy in HER2-Positive Breast Cancer
Adjuvant anti-HER2 therapy in combination with chemotherapy has markedly improved disease-free survival and overall ...
JULY 12, 2017
